Shots: The approval is based on P-II assessing Zepzelca in 105 adults Ultragenyx with SCLC at 26 hospitals in the US and EU The study resulted in ORR was 35%, median […]readmore
Tags : Lurbinectedin
Shots: The US FDA has accepted NDA filing with PR seeking accelerated approval for lurbinectedin to treat patients with SCLC having diseases progression following the prior treatment of platinum-containing therapy […]readmore
Shots: Lurbinectedin (PM1183) a compound under clinical investigation an inhibitor of RNA polymerase II, essential for transcription process that is over-activated in tumors with transcription addiction The designation may provide […]readmore